Phil Sutton

Dr. Phil Sutton


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2011 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
MMMichael McGuckin
Michael McGuckin
SLSara K. Lindén
Sara K. Lindén
PSPhil Sutton
Phil Sutton
TFTimothy H. Florin
Timothy H. Florin

5 March 2008 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
SLS K Linden
S K Linden
PSPhil Sutton
Phil Sutton
NKNiclas Karlsson
Niclas Karlsson
Victoria KorolikVictoria Korolik
Victoria Korolik
MMMichael McGuckin
Michael McGuckin
The mucosal tissues of the gastrointestinal, respiratory, reproductive, and urinary tracts, and the surface of the eye present an enormous surface area to the exterior environment. All of these tissues are covered with resident microbial flora, which vary considerably in composition and complexity. Mucosal tissues represent the site of infection or route of access for the majority of viruses, bacteria, yeast, protozoa, and multicellular parasites that cause human disease. Mucin glycoproteins are secreted in large quantities by mucosal epithelia, and cell surface mucins are a prominent feature of the apical glycocalyx of all mucosal epithelia. In this review, we highlight the central role played by mucins in accommodating the resident commensal flora and limiting infectious disease, interplay between underlying innate and adaptive immunity and mucins, and the strategies used by successful mucosal pathogens to subvert or avoid the mucin barrier, with a particular focus on bacteria.

9 October 2009 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SLSara Linden
Sara Linden
YSYong H. Sheng
Yong H. Sheng
AEAlison L. Every
Alison L. Every
KMKim M. Miles
Kim M. Miles
ESEmma C. Skoog
Emma C. Skoog
MMMichael McGuckin
Michael McGuckin
The bacterium Helicobacter pylori can cause peptic ulcer disease, gastric adenocarcinoma and MALT lymphoma. The cell-surface mucin MUC1 is a large glycoprotein which is highly expressed on the mucosal surface and limits the density of H. pylori in a murine infection model. We now demonstrate that by using the BabA and SabA adhesins, H. pylori bind MUC1 isolated from human gastric cells and MUC1 shed into gastric juice. Both H. pylori carrying these adhesins, and beads coated with MUC1 antibodies, induced shedding of MUC1 from MKN7 human gastric epithelial cells, and shed MUC1 was found bound to H. pylori. Shedding of MUC1 from non-infected cells was not mediated by the known MUC1 sheddases ADAM17 and MMP-14. However, knockdown of MMP-14 partially affected MUC1 release early in infection, whereas ADAM17 had no effect. Thus, it is likely that shedding is mediated both by proteases and by disassociation of the non-covalent interaction between the α- and β-subunits. H. pylori bound more readily to MUC1 depleted cells even when the bacteria lacked the BabA and SabA adhesins, showing that MUC1 inhibits attachment even when bacteria cannot bind to the mucin. Bacteria lacking both the BabA and SabA adhesins caused less apoptosis in MKN7 cells than wild-type bacteria, having a greater effect than deletion of the CagA pathogenicity gene. Deficiency of MUC1/Muc1 resulted in increased epithelial cell apoptosis, both in MKN7 cells in vitro, and in H. pylori infected mice. Thus, MUC1 protects the epithelium from non-MUC1 binding bacteria by inhibiting adhesion to the cell surface by steric hindrance, and from MUC1-binding bacteria by acting as a releasable decoy. The bacterium Helicobacter pylori can cause peptic ulcer disease, gastric adenocarcinoma and MALT lymphoma. H. pylori colonize the mucosal surface of the stomach, where adherence helps the bacteria to remain in the neutral and protected niche under the mucus layer, and helps it withstand the continuous mucus washing of the mucosal surface. Adherence is also thought to mediate much of the H. pylori mediated disease. The cell-surface mucin MUC1 is highly expressed on the mucosal surface and limits the density of H. pylori in a murine infection model. We now demonstrate that the majority of H. pylori strains can bind to human MUC1 and that release of MUC1 following binding limits adhesion to the cell surface. Furthermore, MUC1 protects the epithelium from non-MUC1 binding bacteria by acting as a physical barrier to adhesion to other cell surface molecules. Thus, appropriate expression and function of MUC1 is likely to limit development of disease ensuing from chronic H. pylori infection.

1 October 2007 in Gastroenterology
Verified
Journal Article
Open access
PDF file
MMMichael McGuckin
Michael McGuckin
AEAlison L. Every
Alison L. Every
CSCaroline D. Skene
Caroline D. Skene
SLSara K. Linden
Sara K. Linden
YCYok Teng Chionh
Yok Teng Chionh
PSPhil Sutton
Phil Sutton
The MUC1 mucin is expressed on the cell surface of epithelial cells lining the gastric mucosa. Epidemiologic studies suggest that functional allelic variations in the MUC1 gene may play a role in human susceptibility to Helicobacter pylori-associated pathologies, including gastric adenocarcinoma. We have evaluated the impact of Muc1 expression on the colonization and pathogenesis of gastric Helicobacter infections. Wild-type and Muc1-deficient mice were infected with H pylori and colonization and gastritis levels determined. Primary gastric cells were used to examine the impact of Muc1 expression on bacterial adherence. Mice lacking Muc1 were colonized by 5-fold more H pylori within 1 day of infection, and this difference was maintained for at least 2 months postinfection. Mice heterozygous for the null Muc1 allele developed intermediate bacterial colonization. Although wild-type mice developed only a mild gastritis when infected for 2 months with H pylori, Muc1(-/-) mice developed an atrophic gastritis marked by loss of parietal cells. We demonstrate H pylori adhesion to purified MUC1 and significantly increased adhesion to cultured murine Muc1 null gastric epithelial cells, suggesting that Muc1 acts as a decoy limiting binding to the cell surface. Muc1 provides a protective barrier, which limits both acute and chronic colonization by H pylori, as well as playing a major role in limiting the inflammation induced by Helicobacter infection. We propose that Muc1 restricts access of H pylori to the epithelial surface, hence reducing exposure of the host to proinflammatory bacterial products.

1 April 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KSKevin J. Selva
Kevin J. Selva
Carolien Emma van de SandtCarolien Emma van de Sandt
Carolien Emma van de Sandt
MLMelissa M. Lemke
Melissa M. Lemke
CLChristina Y. Lee
Christina Y. Lee
SSSuzanne K. Shoffner
Suzanne K. Shoffner
ACAmy W. Chung
Amy W. Chung
The hallmarks of COVID-19 are higher pathogenicity and mortality in the elderly compared to children. Examining baseline SARS-CoV-2 cross-reactive immunological responses, induced by circulating human coronaviruses (hCoVs), is needed to understand such divergent clinical outcomes. Here we show analysis of coronavirus antibody responses of pre-pandemic healthy children (n = 89), adults (n = 98), elderly (n = 57), and COVID-19 patients (n = 50) by systems serology. Moderate levels of cross-reactive, but non-neutralizing, SARS-CoV-2 antibodies are detected in pre-pandemic healthy individuals. SARS-CoV-2 antigen-specific Fcγ receptor binding accurately distinguishes COVID-19 patients from healthy individuals, suggesting that SARS-CoV-2 infection induces qualitative changes to antibody Fc, enhancing Fcγ receptor engagement. Higher cross-reactive SARS-CoV-2 IgA and IgG are observed in healthy elderly, while healthy children display elevated SARS-CoV-2 IgM, suggesting that children have fewer hCoV exposures, resulting in less-experienced but more polyreactive humoral immunity. Age-dependent analysis of COVID-19 patients, confirms elevated class-switched antibodies in elderly, while children have stronger Fc responses which we demonstrate are functionally different. These insights will inform COVID-19 vaccination strategies, improved serological diagnostics and therapeutics.

1 May 2008 in Trends in Biotechnology
Verified
Journal Article
Closed access
JSJean-Pierre Scheerlinck
Jean-Pierre Scheerlinck
KSKenneth J. Snibson
Kenneth J. Snibson
VBVernon M. Bowles
Vernon M. Bowles
PSPhil Sutton
Phil Sutton